ES3039536T3 - Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound - Google Patents

Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Info

Publication number
ES3039536T3
ES3039536T3 ES21755253T ES21755253T ES3039536T3 ES 3039536 T3 ES3039536 T3 ES 3039536T3 ES 21755253 T ES21755253 T ES 21755253T ES 21755253 T ES21755253 T ES 21755253T ES 3039536 T3 ES3039536 T3 ES 3039536T3
Authority
ES
Spain
Prior art keywords
compound
day
dose
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21755253T
Other languages
English (en)
Spanish (es)
Inventor
William Brian Kielbasa
Dustin James Mergott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES3039536T3 publication Critical patent/ES3039536T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES21755253T 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound Active ES3039536T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23
PCT/US2021/042877 WO2022020663A1 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Publications (1)

Publication Number Publication Date
ES3039536T3 true ES3039536T3 (en) 2025-10-22

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21755253T Active ES3039536T3 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Also Published As

Publication number Publication date
CL2023000194A1 (es) 2023-07-21
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
AU2021312894B2 (en) 2025-09-11
PE20231031A1 (es) 2023-07-10
IL300023A (en) 2023-03-01
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
PH12023550177A1 (en) 2024-03-18
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15
TW202220650A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7046241B2 (ja) ポンペ病の処置のための投与計画
ES2547916T3 (es) Terapia de combinación de inhibidores de mTOR/JAK
Fowler et al. Mapping cocaine binding sites in human and baboon brain in vivo
Naseem et al. Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers
KR102961896B1 (ko) 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
US20080004284A1 (en) Method for treating fibromyalgia syndrome and related conditions
JP6966840B2 (ja) 神経変性疾患の改善用医薬
ES2952672T3 (es) Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
WO2014134569A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2018531605A5 (cg-RX-API-DMAC7.html)
Davidson et al. Action and metabolism of chlorpromazine sulfoxide in man
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
US20210338670A1 (en) Non-invasive pet imaging of cdk4/6 activation in cancer
CA3170685A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
US20240245666A1 (en) Dosing regimens
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
HK40084518A (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
Asheesh et al. Teriflunomide: a Novel Oral Disease-Modifying Agent Under Investigation for the Treatment of Multiple Sclerosis
Steele et al. Pharmacology and the elderly
WO2025188951A1 (en) Fused amino pyrimidine compounds for treatment of seizure disorders
WO2025188953A1 (en) Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain
EP4687861A1 (en) Compositions comprising 5-methoxy-2-aminoindan for treatment of depression